Investing Ideas
/
U.S. Pharmaceuticals & Biotech Large Cap High Growth Potential

U.S. Pharmaceuticals & Biotech Large Cap High Growth Potential

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.

20 companies

Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
ALNY Alnylam Pharmaceuticals	US$250.59	-2.3%	59.0%	US$32.5b	US$301.27	PS14.4x	E59.1%	n/a
ITCI Intra-Cellular Therapies	US$128.60	0.6%	83.3%	US$13.7b	US$132.73	PS20.1x	E50.6%	n/a
SRPT Sarepta Therapeutics	US$106.28	-1.5%	-22.2%	US$10.4b	US$181.78	PE83.3x	E30.1%	n/a
NBIX Neurocrine Biosciences	US$120.69	4.9%	-10.1%	US$11.6b	US$166.45	PE35.3x	E27.2%	n/a
ONC BeiGene	US$255.37	10.6%	64.6%	US$26.1b	US$285.04	PS8.4x	E67.0%	n/a
LLY Eli Lilly	US$873.68	3.5%	13.5%	US$784.2b	US$981.47	PE74.1x	E21.7%	0.7%
VRTX Vertex Pharmaceuticals	US$484.24	5.5%	12.6%	US$123.3b	US$497.91	PS11.3x	E29.4%	n/a
ILMN Illumina	US$94.20	-6.0%	-29.2%	US$15.4b	US$145.92	PS3.4x	E52.3%	3.3%
ABBV AbbVie	US$202.08	4.8%	13.5%	US$354.6b	US$204.90	PE84.2x	E25.3%	3.2%
BMY Bristol-Myers Squibb	US$55.83	3.6%	8.1%	US$113.2b	US$61.34	PS2.3x	E34.4%	4.4%
TECH Bio-Techne	US$64.92	-1.5%	-9.4%	US$10.4b	US$85.42	PE64.9x	E21.9%	0.5%
INCY Incyte	US$72.11	2.4%	19.0%	US$13.8b	US$78.26	PE427.9x	E22.3%	n/a
TEVA Teva Pharmaceutical Industries	US$16.74	3.0%	29.9%	US$19.5b	US$23.90	PS1.2x	E66.6%	0%
GILD Gilead Sciences	US$109.95	5.6%	49.5%	US$137.1b	US$107.59	PE285.5x	E23.6%	2.9%
NTRA Natera	US$162.31	-6.4%	130.4%	US$22.2b	US$179.67	PS14x	E70.4%	n/a
VTRS Viatris	US$11.25	4.2%	-16.9%	US$13.2b	US$13.20	PS0.9x	E52.4%	4.3%
MEDP Medpace Holdings	US$340.22	0.01%	-15.3%	US$10.5b	US$344.83	PE25.6x	E9.6%	n/a
RVTY Revvity	US$113.84	1.4%	9.0%	US$14.0b	US$141.19	PE48.9x	E20.2%	0.2%
AMGN Amgen	US$303.01	4.1%	4.8%	US$160.0b	US$315.60	PE39.8x	E16.3%	3.1%
BMRN BioMarin Pharmaceutical	US$68.25	5.2%	-25.2%	US$13.1b	US$96.71	PE30.5x	E20.2%	n/a

Page 1 of 1